Lopinavir-Ritonavir and Liver Involvement in Patients With COVID-19

被引：0
|
作者：
Lv, Xiu-He [1 ,2 ]
Yang, Jin-Lin [1 ,2 ]
Deng, Kai [1 ,2 ,3 ,4 ]
机构：
[1] Sichuan Univ, West China Hosp, Dept Gastroenterol & Hepatol, Chengdu, Sichuan, Peoples R China
[2] Sichuan Univ, West China Hosp, Sichuan Univ Oxford Univ Huaxi Gastrointestinal C, Dept Gastroenterol & Hepatol, Chengdu, Sichuan, Peoples R China
[3] Sichuan Univ, West China Hosp, COVID 19 Med Team Hubei, Chengdu, Sichuan, Peoples R China
[4] Wuhan Univ, Renmin Hosp, East Branch, COVID 19 Med Team Hubei,West China Hosp, Wuhan, Hubei, Peoples R China
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2021年 / 116卷 / 05期
关键词：
LOPINAVIR/RITONAVIR;
D O I：
10.14309/ajg.0000000000001043
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1099 / 1099
页数：1
相关论文
共 50 条
  • [41] Hyponatraemia associated with lopinavir-ritonavir?
    Roberts, M. T. M.
    Aliyu, S. H.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2007, 11 (01) : 83 - 84
  • [42] In severe COVID-19, adding lopinavir-ritonavir to usual care did not improve mortality at 28 days
    Singh, Ameeta
    ANNALS OF INTERNAL MEDICINE, 2021, 174 (01) : JC3 - JC3
  • [43] Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
    Mohsenian Naghani, Shaghayegh
    Jansen, Mark M. P. M.
    Jaspers, Tessa
    Bastiaans, Diane
    Burger, David
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2023, 30 (E1) : E106 - E108
  • [44] Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients
    Russo, Vincenzo
    Carbone, Andreina
    Mottola, Filiberto Fausto
    Mocerino, Rosa
    Verde, Raffaele
    Attena, Emilio
    Verde, Nicoletta
    Di Micco, Pierpaolo
    Nunziata, Luigi
    Santelli, Francesco
    Nigro, Gerardo
    Severino, Sergio
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [45] Serotonin syndrome in two COVID-19 patients treated with lopinavir/ritonavir
    Mas Serrano, Miguel
    Ricardo Perez-Sanchez, Javier
    Portela Sanchez, Sofia
    De la Casa-Fages, Beatriz
    Mato Jimeno, Victor
    Perez Tamayo, Isabel
    Grandas, Francisco
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2020, 415
  • [46] Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study
    Elmekaty, Eman Zeyad, I
    Alibrahim, Rim
    Hassanin, Rania
    Eltaib, Sitelbanat
    Elsayed, Ahmed
    Rustom, Fatima
    Ibrahim, Mohamed Izham Mohamed
    Abu Khattab, Mohammed
    Al Soub, Hussam
    Al Maslamani, Muna
    Al-Khal, Abdullatif
    PLOS ONE, 2022, 17 (05):
  • [47] Adverse effects of lopinavir/ritonavir in critically ill patients with COVID-19
    Vecchio, Gisela
    Zapico, Valeria
    Catanzariti, Alejandro
    Carboni Bisso, Indalecio
    Las Heras, Marcos
    MEDICINA-BUENOS AIRES, 2020, 80 (05) : 439 - 441
  • [48] Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?
    Baldelli, Sara
    Corbellino, Mario
    Clementi, Emilio
    Cattaneo, Dario
    Gervasoni, Cristina
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (09) : 2704 - 2706
  • [49] Lopinavir / ritonavir for COVID-19: A living systematic review
    Verdugo-Paiva, Francisca
    Izcovich, Ariel
    Ragusa, Martin
    Rada, Gabriel
    MEDWAVE, 2020, 20 (06):
  • [50] Hair loss induced by lopinavir-ritonavir
    Borras-Blasco, Joaquin
    Belda, Alberto
    Rosique-Robles, Dolores
    Castera, Elvira
    Abad, Javier
    Amoros-Quiles, Isabel
    PHARMACOTHERAPY, 2007, 27 (08): : 1215 - 1218
12345